CANbridge Pharmaceuticals begins CAN103 phase 1/2 trial in Gaucher disease
CANbridge Pharmaceuticals said that it has dosed the first patient in a phase 1/2 trial of CAN103 in treatment-naïve patients in China having Gaucher disease (GD) Types I and III. The clinical trial of the recombinant human glucocerebrosidase enzyme replacement therapy is likely to enroll nearly 40 Gaucher disease patients. Gaucher disease is a lysosomal […]